Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) hit a new 52-week high on Thursday . The stock traded as high as $4.09 and last traded at $4.28, with a volume of 17629594 shares traded. The stock had previously closed at $3.18.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the stock. Bank of America began coverage on shares of Taysha Gene Therapies in a report on Friday, July 11th. They issued a "buy" rating and a $8.00 target price for the company. Needham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, July 1st. Wells Fargo & Company upped their target price on Taysha Gene Therapies from $7.50 to $8.00 and gave the company an "overweight" rating in a report on Wednesday, August 13th. Finally, Chardan Capital raised their price target on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of "Buy" and an average price target of $8.29.
Get Our Latest Analysis on Taysha Gene Therapies
Taysha Gene Therapies Stock Up 39.2%
The stock has a 50 day simple moving average of $2.94 and a 200-day simple moving average of $2.43. The firm has a market cap of $1.21 billion, a PE ratio of -13.01 and a beta of 0.99. The company has a debt-to-equity ratio of 0.17, a current ratio of 12.48 and a quick ratio of 12.48.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. The firm had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.61 million. Sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.
Insider Buying and Selling
In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total value of $646,000.00. Following the transaction, the insider owned 1,006,439 shares of the company's stock, valued at approximately $3,250,797.97. This represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.78% of the company's stock.
Hedge Funds Weigh In On Taysha Gene Therapies
A number of institutional investors have recently bought and sold shares of TSHA. Marex Group plc bought a new stake in Taysha Gene Therapies during the 2nd quarter worth approximately $29,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies in the second quarter worth $31,000. May Hill Capital LLC bought a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at about $37,000. Ameriprise Financial Inc. purchased a new stake in Taysha Gene Therapies during the fourth quarter valued at approximately $40,000. Finally, BNP Paribas Financial Markets bought a new stake in Taysha Gene Therapies in the fourth quarter worth $41,000. 77.70% of the stock is owned by institutional investors.
About Taysha Gene Therapies
(
Get Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
